24.01.2012
- European regulators took another step towards opening the market for copies of biotech drugs on by releasing a draft guideline on how companies should test biosimilar medicines...
27.07.2011
- Biogen Idec posted second-quarter net income attributable to the company of $288.03 million or $1.18 per share compared to $293.44 million or $1.12 per share last year. Non-GAAP...
30.05.2011
- Doubled-Edged Sword - The emergence of biosimilars has caused very large ripples in the biopharma pond, and has recently been called the most "disruptive technology" of the decade...
21.03.2011
- Biogen Idec's board is proposing that all directors be elected on an annual basis as opposed to the current process of staggered term elections, the company said on Friday. The...
26.01.2011
- Late last year, a handful of executives from Irish drugmaker Elan Corp flew by private jet from San Francisco to New York to notify the board they planned to lay off 130 workers...
21.12.2010
- Genzyme argued that its experimental multiple sclerosis treatment will garner far higher sales than Sanofi-Aventis is projecting, as it aims to wrest a significantly higher bid...
09.08.2010
- Paris-based drugmaker Sanofi-Aventis may need weeks of haggling to get a deal on buying U.S. biotech firm Genzyme as the two appear wide apart over price. Neither party has...
04.08.2010
- Sanofi-Aventis has grabbed the headlines with its $18.4 billion bid for Genzyme, but the French drugmaker may be wiser to stick with smaller, bolt-on acquisitions. Sanofi is trying...
